Breast cancer is the second leading cause of cancer death among women in the United States. Approximately 215 000 women were diagnosed with invasive breast cancer, 50 000 women were diagnosed with ductal carcinoma in situ, and 40 000 women died of invasive breast cancer in 2005 (1). Worldwide, it is estimated that more than 1 million women are diagnosed with breast cancer every year, and more than 410 000 will die of the disease (2). Tobacco, one of the most widely examined environmental factors, contains human carcinogens and may contribute to a woman's risk of developing breast cancer (3). Epidemiological cohort studies with large numbers of participants in the United States and Japan have indicated that breast cancer risk is associated with active and passive smoking (4, 5) .
Background
Large epidemiological cohort studies in the United States have indicated that active and passive smoking are associated with increased breast cancer risk. However, there was no direct evidence of an effect of tobacco carcinogens on the cellular molecules involved in breast tumorigenesis.
Methods
Reverse transcription-polymerase chain reaction was used to determine the expression of all of the nicotinic acetylcholine receptor (nAChR) subunits in 50 human breast cancer samples and to determine the expression of the a9-nAChR subunit in 276 surgical and laser capture microdissected breast tumor vs normal tissue pairs. Stable MDA-MB-231 breast cancer cell lines were established in which expression of the a9-nAChR subunit was inhibited using short interfering RNA. MCF-10A normal human breast epithelial cells were established in which the a9-nAChR subunit could be conditionally overexpressed by removal of doxycycline from the culture fluid. Cell proliferation and soft agar assays and tumor growth in nude mice were used as measures of cell transformation. All statistical tests were two-sided.
Results
In 186 (67.3%) of the 276 paired samples, a9-nAChR mRNA was expressed at (mean 7.84-fold) higher levels in breast cancers than in surrounding normal tissue. Stable expression of a9-nAChR short interfering RNA in MDA-MB-231 cells attenuated nicotine-stimulated proliferation and growth in soft agar and reduced tumor volume when the cells were introduced as xenografts in SCID mice (n = 5 mice per group; mean tumor volume at 6 weeks treatment in mice injected with Si a9 cells = 995.6 mm 3 , in mice injected with parental cells = 2993.2 mm 3 , difference = 1997.6 mm 3 , 95% confidence interval [CI] = 1705 to 2290.2 mm 3 , P = .009). Long-term treatment of MCF-10A normal breast epithelial cells with either nicotine or its active metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, triggered precancerous transformation as defined by soft agar assay. Inducible overexpression of a9-nAChR in MCF-10A cell xenografts in nude mice substantially increased tumor growth (n = 5 mice per group; DOX+, mean tumor volume without nicotine vs with nicotine = 266.2 vs 501.6 mm 3 , difference = 235.4 mm 3 , 95% CI = 112.7 to 358 mm 3 , P = .009; DOX2, mean tumor volume without nicotine vs with nicotine = 621.2 vs 898.6 mm 3 , difference = 277.4 mm 3 , 95% CI = 98.1 to 456.7 mm 3 , P = .016; mean tumor volume in the presence of nicotine, DOX+ vs DOX2 = 501.6 vs 898.6 mm 3 , difference = 397 mm 3 , 95% CI = 241.3 to 552.6 mm 3 , P = .009).
Conclusion
The a9-nAChR is important for nicotine-induced transformation of normal human breast epithelial cells.
smoking of a single cigarette (6) . Studies using 14 C-nicotine have shown that from 80% to 90% of inhaled nicotine is absorbed (7) . Nicotine concentrations in plasma average about 15 ng/mL immediately after smoking and are extremely high in the saliva and gastric juice (>1300 and >800 ng/mL, respectively) (8) .
Previous studies using a soft agar transforming assay and a mouse xenograft model demonstrated that noncancerous MCF-10A human breast epithelial cells can become neoplastically transformed by exposure to either a cigarette smoke condensate or the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (9, 10) . Repeated exposure of MCF-10A cells to NNK resulted in anchorage-independent growth and reduced growth factor dependence (10) . In vivo studies have demonstrated that nicotine promotes the growth of solid tumors, suggesting that nicotine might contribute to the progression of cell proliferation, invasion, and angiogenesis in tumors (11) (12) (13) . These results imply that nicotinic alteration of normal breast epithelial cells may also contribute to breast tumorigenesis.
Human neuronal tissues have been reported to have the most abundant expression of the nicotinic acetylcholine receptor (nAChR) subunit. nAChRs occur as heteropentamers comprising a combination of a subunits (a1-a6) and b subunits (b2-b4) or as homopentamers derived from subunits a7-a10 symmetrically arranged around a central ion pore (14, 15) . However, reverse transcriptionpolymerase chain reaction (RT-PCR), immunoblotting, and flow cytometry analyses have provided considerable evidence for the expression of nAChRs in nonneuronal cells outside the nervous system, including bronchial epithelium membranes and endothelial cells (16, 17) . The physiological ligand of nAChRs is acetylcholine; however, tobacco components like nicotine and NNK are also known to be high-affinity nAChR agonists (18, 19) . Several studies have reported roles for the nAChRs in carcinogenesis, which include angiogenesis (13) , proliferation (20, 21) , and the inhibition of apoptosis (22, 23) . Cigarette smoking is known to be a prominent risk factor for lung (16) , colon (24) , and bladder cancers (25) , all of which express a7 as a major nAChR, as well as breast cancers, which express a9-nAChR, suggesting that agents like nicotine and NNK may function in a receptor-dependent manner (11, 16, 20, 26) .
Unlike the nAChRs that are expressed in normal neuronal cells, most of the nAChRs present in cancer cell lines have not been functionally characterized (17) . Characterization is important because nonneuronal nAChRs in human cancer cells could be potential molecular targets for clinical therapeutic purposes (27) . Therapeutic strategies involving activation of neuronal a7-nAChRs have been considered for the treatment of Alzheimer disease and schizophrenia (28) . In cancer cells, nAChRs could also play a role in the acquisition of chemotherapy drug resistance: Nicotine has been shown to protect cells against apoptosis, so nAChR antagonists could potentially be used in combination with established chemotherapeutic drugs to enhance therapeutic responses to chemotherapy (27, 29) .
In this study, we sought to determine whether inhibition of a9-nAChR subunit expression in human breast cancer cells can substantially inhibit tumor growth in vivo. To explore the potential carcinogenic effects of the a9-nAChR subunit, which is expressed in normal human breast epithelial cells, we established MCF-10A normal human breast cells with tetracycline-regulated (Tet-off) overexpression of a9-nAChR. We then performed in vivo studies that used the MCF-10A-Nic cells with conditional overexpression of the a9-nAChR or MDA-MB-231 human breast cancer cells with short interfering RNA (siRNA) to reduce a9-nAChR expression levels to investigate the role of a9-nAChR in nicotineinduced breast carcinogenesis.
Subjects and Methods

Cell Culture and Patient Samples
All human breast tumor samples (n = 276) were obtained as specimens from anonymous donors from Taipei Medical University Hospital and Cathay General Hospital, Taipei, Taiwan, according to a protocol approved by the Institutional Review Board (P950012). On histological inspection, all patient samples consisted of more than 80% tumor tissue. All samples (each paired tumor vs normal tissue) were collected and categorized according to the clinical information such as stage status. Human mammary gland epithelial
CONTEXT AND CAVEATS
Prior knowledge
Although smoking is an established risk factor for breast cancer, a direct role for the a9-nicotinic acetylcholine receptor (a9-nAChR) in nicotine-induced carcinogenesis has not been shown.
Study design
Paired normal and breast tumor cells were examined for the expression of the a9-nAChR subunit. MDA-MB-231 human breast cancer cell lines in which a9-nAChR expression was silenced by RNA interference and MCF-10A (DOX) normal human breast cells in which a9-nAChR overexpression was induced by doxycycline withdrawal were established to study the role of the a9-nAChR in nicotine-induced breast carcinogenesis.
Contribution
Human breast cells consistently expressed a9-nAChR mRNA, and expression was higher in tumor samples than in normal samples and in advanced-stage breast cancers compared with early-stage cancers. Nicotine-stimulated cell proliferation was attenuated, and nicotine-stimulated anchorage-independent growth was inhibited by expression of a9-nAChR siRNA. In mice that were treated with nicotine, tumors that arose from xenografts of MDA-MB-231 cells carrying a9-nAChR siRNA were smaller than those from parental cell xenografts. MCF-10A (DOX2) cells treated long-term with nicotine or a metabolite became transformed as defined by soft agar colony formation. Mice implanted with MCF-10A DOX cells grew more tumors in the presence than in the absence of nicotine when the a9-nAChR was overexpressed.
Implications
Nicotine may transform some cells directly by activation of the a9 subunit of the nAChR.
Limitations
Expression of the a9-nAChR was studied in a limited number of clinical samples, all from Asian women. RNA interference with a9-nAChR expression and conditional overexpression of a9-nAChR were each examined in a single human breast cell line.
From the Editors
adenocarcinomas (MCF-7, MDA-MB-231, AU-565, MDA-MB-453, and BT-483) and human normal mammary gland epithelial fibrocystic cell lines (MCF-10A and HBL-100) were purchased from the American Tissue Cell Culture collection (Manassas, VA). MCF-10A cells were maintained in complete MCF-10A culture medium, that is, a 1:1 mixture of Dulbecco's modified Eagle medium (DMEM) and Ham F12 supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin, 0.5 µg/mL hydrocortisol, and 20 ng/mL epidermal growth factor (Life Technologies, Rockville, MD). MCF-7, MDA-MB-231, HBL-100, and MDA-MB-453 cells were maintained in DMEM, whereas AU-565 and BT-483 cells were maintained in RPMI-1640.
Cell Proliferation and Viability Assays
Cell growth, proliferation, and viability were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay (30) . Stock solutions of 10 mM nicotine and NNK (Chemsyn, Lenexa, KS) were prepared in dimethyl sulfoxide. This assay was repeated four times with duplicate samples.
RNA Isolation and Real-Time Quantitative PCR
Total RNA was isolated from both human cell lines and breast tumor tissue samples acquired directly from patients (n = 276) using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. A portion of the samples from the original group (n = 50 of 276) were randomly selected for the determination of nAChR expression profiles by RT-PCR. After random selection, the clinical information associated with these samples was carefully checked to ensure that there were no substantial differences between the selected and the original groups (Supplementary  Table 1 , available online). The nAChR subunit-specific primers were synthesized as previously described (16) (Supplementary  Table 2 , available online). A LightCycler thermocycler (Roche Molecular Biochemicals, Mannheim, Germany) was used for the real-time quantitative PCR. The a9-nAChR mRNA fluorescence intensity was measured and normalized to b-glucuronidase expression using the built-in software (Roche LightCycler Version 4).
RNA Interference
Both a5-and a9-nAChR expression were each ablated in MDA-MB-231 breast cancer cell with at least two independent siRNAs. Scrambled sequences of each siRNA were used as controls (Supplementary Table 2 , available online). After BLAST analysis to verify the absence of significant sequence homologies with other human genes, the selected sequences were inserted into BglII and HindIII-cut pSUPER vectors to generate the pSUPER-Si a5-nAChR, pSUPER-Si a9-nAChR, and pSUPER-scramble vectors. The identities of all constructs were confirmed by DNA sequence analysis. The transfection protocol has been described previously (31) . Briefly, 1.5 × 10 5 cells were washed twice with phosphate-buffered saline and mixed with 0.5 µg of plasmid. One pulse was applied for a duration of 20 milliseconds under a fixed voltage of 1.2 kV on a pipette-type microporator MP-100 (Digital Bio, Seoul, Korea).
Generation of Stable nAChR siRNA-Expressing Cell Lines
At least three clones of the MDA-MB-231 cell lines were generated that stably expressed siRNAs to a5-nAChR or a9-nAChR or scrambled control siRNA. All experiments were performed using multiple subclones of each cell line, with reproducible results. The pSUPER-Si a5-nAChR, pSUPER-Si a9-nAChR, and pSUPERscramble vectors were transfected, and stable integrants were selected 72 hours later with G418 (4 mg/mL). After 30 days in selective medium, two G418-resistant clones, referred to as Si a5-nAChR (Si a5) and Si a9-nAChR (Si a9), were isolated; these clones demonstrated more than 80% reduction in mRNA and protein levels when compared with the control clones (scramble control, Sc).
In Vivo Treatment of Mice With a9-nAChR siRNAExpressing Breast Cancer Cell Xenografts MDA-MB-231 cell lines with stable integration of pSUPER-Si a9 or pSUPER-Si a9 scramble sequences were established by G418 selection. The cells (5 × 10 6 ) were implanted subcutaneously into each 6-week-old NOD.CB17-PRKDC(SCID)/J(NOD-SCID) mice (n = 5) (purchased from National Science Council Animal Center, Taipei, Taiwan). After tumor transplantation, nicotine (10 mg/mL) was administered via the drinking water for 6 weeks until the mice were killed by anesthesia with ether. During the experiment, the tumor size was measured using calipers and the tumor volume was estimated by using the formula: tumor volume (mm
, where L is the length and W is the width of the tumor (32) . At the end of experiment, subcutaneous tumor masses were dissected from the mice and weighing them. All mouse protocols were performed according to an Association for Assessment and Accreditation of Laboratory Animal Care-approved protocol.
Generation of Nicotine-and NNK-Transformed MCF-10A Cells
We treated MCF-10A cells with a low dose of nicotine (10 µM) and NNK (1 µM) to mimic long-term exposure of cells to these carcinogens (9, 33) . Cells were subcultured every 4 days, and cells were treated with nicotine and NNK for 48 hours after every passage. After 2 months, the nicotine-and NNK-transformed cells (MCF-10A-Nic and MCF-10A-NNK) were transfected with adenoviruses carrying conditionally regulated (Tet-off) a9-nAChR transgenes.
Construction of a9-nAChR Adenovirus Tet-Off Expression Vectors
A PCR fragment encompassing the coding region of the a9-nAChR gene was generated using a forward primer, 5′-GTTGAA-TTCATGAACTGGTCCCATTCCTGC-3′, adapted with an EcoRI site and a reverse primer, 5′-GATGGATCCCTAATCC-GCTCTTGCTATGAT-3′, that contained a BamHI site (Supplementary Table 2 , available online). After digestion with EcoRI and BamHI, the fragment was ligated into the pTRE-Shuttle vector. The integrity of the constructed vector was verified by restriction digestion and DNA sequence analysis. The Tet-responsive expression cassette was excised from the recombinant pTRE-Shuttle plasmids using the I-CeuI and I-SceI endonucleases and ligated into the predigested Adeno-X viral DNA. Recombinant Adeno-X viral DNA was propagated in Escherichia coli, linearized by digestion with PacI, and transfected into low-passage HEK 293 cells. HEK 293 cells were infected with the recombinant virus, and the growth medium was collected when 80% of the cells had detached from the culture plate to produce high-titer adenovirus stocks.
Generation of Adeno-X Tet-off a9-nAChR-Overexpressing Cells
The nicotine-and NNK-transformed (MCF-10A-Nic and MCF-10A-NNK) cells were plated in 60-mm dishes at a density of 10 6 cells per dish. Two days later, the cells were coinfected with the Tet-responsive recombinant virus and the tetracycline-controlled transactivator virus (BD Adeno-X Tet-off system; Clontech, Palo Alto, CA) at a multiplicity of infection of approximately five plaque-forming units of each virus strain per cell. After incubation for 12 hours at 37°C in a CO 2 incubator, the virus-containing medium was removed and fresh growth medium containing 10% serum was added in both the presence and absence of 1 µg/mL of the tetracycline analog doxycycline (DOX) (DOX+ or DOX2). This resulted in the establishment of MCF-10A-Nic (DOX) and MCF-10A-NNK (DOX) cells in which a9-nAChR gene expression was induced by removal of DOX.
Isolation of Transformed Adeno-X Tet-off a9-nAChR-
Overexpressing Cells
The transformed MCF-10A-Nic (DOX) and MCF-10A-NNK (DOX) cells were plated onto soft agar (see below). After 21 days, colonies were isolated from soft agar and incubated with 0.5% trypsin for 10 minutes as in previous studies (9, 33) . Cells were dispersed in complete MCF-10A culture medium, maintained at 37°C, and cultured as cell lines. ) were divided into either a9-nAChR mRNA expressing (DOX2) or noninduced (DOX+) groups, the latter of which could express the a9-nAChR mRNA at basal level. The mice were simultaneously treated with or without nicotine (10 mg/mL) in their drinking water for an additional 6 weeks. The xenografts were weighed and either snap-frozen in dry ice and stored at 280°C for RNA and protein analysis or formalin-fixed and paraffin-embedded for immunohistochemical observation.
Soft Agar Growth Assay
Protein Extraction, Western Blotting, and Antibodies
For determination of a9-nAChR protein expression, the Si a5, Si a9, Sc, and MCF-10A-Nic (DOX+/2) cells were washed once with ice-cold phosphate-buffered saline and lysed on ice in cell lysis buffer (50 mM Tris-HCl, pH 8.0; 120 mM NaCl 2 ; 0.5% Nonidet P-40; 100 mM sodium fluoride; and 200 µM sodium orthovanadate) containing protease inhibitors, as previously described (21) . Xenograft tumor tissues were thawed in 750 µL of lysis buffer containing protease inhibitors to examine protein expression. The samples were homogenized three times at setting 3 (18 000 rpm) on ice using a PRO 200 homogenizer (PRO Scientific, Inc, Monroe, CT). Protein (50 µg) from each sample was resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane, and analyzed by western blotting. Mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody and rabbit polyclonal anti-a9-nAChR antibody were purchased from Abcam, Inc (Cambridge, MA). Alkaline phosphatase-coupled anti-mouse and anti-rabbit IgG secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-GAPDH and anti-a9-nAChR primary antibodies were incubated at 1:2000 and 1:8000 dilution, respectively, for 2 hours, and the secondary antibodies were incubated at 1:4000 dilution for 1 hour. The assay was repeated twice with duplicate samples.
[tissues diagnosed as different stages (stage 1-4, n = 11) were collected. The sections stained with HistGene (Arcturus Engineering, Mountain View, CA) were subjected to laser capture microdissection by using a PixCell IIe system (Arcturus Engineering) (34) . The parameters used for laser capture microdissection included a laser diameter of 8 µm and laser power of 48-65 mW. For each specimen, 15 000 laser pulse discharges were used to capture ~10 000 morphologically normal epithelial cells or malignant carcinoma cells. Each population was visualized under a microscope to make sure that the captured cells were homogeneous. The caps with the captured cells were then fitted onto 0.5 mL Eppendorf tubes containing 42 µL of lysis buffer, and RNA was isolated by following a standard protocol (PicoPure RNA Isolation Kit; Arcturus Bioscience, Mountain View, CA). The purified RNA was then measured by reverse transcription and real-time quantitative PCR analysis.
Immunohistochemistry and Confocal Microscopy
To investigate whether the a9-nAChR could be detected in human breast cancer cell lines, confocal microscopy assay were performed by seeding human breast cancer (MCF-7) cells onto poly-l-lysine-coated slides. The slides were incubated with fluorescein isothiocyanate-labeled anti-a9-nAChR antibodies and rhodamine-labeled anti-caveolin-1 antibodies for 1 hour at room temperature, washed twice with phosphate-buffered saline, and incubated with secondary antibodies for an additional 30 minutes in a moist chamber at room temperature. The slides were then examined with a Leica TCS SP5 Confocal Spectral Microscope Imaging System (Leica Microsystems, Wetzlar, Germany).
The a9-nAChR protein localization in breast tumor tissues was further detected by immunohistochemistry. Paraffin-embedded breast tumor tissues that had been excised either from patients or from xenografted tumors were cut into 8-µM slides. Sections were preincubated in 3% H 2 O 2 and 0.3% Triton X-100 before microwaving for antigen retrieval. For a9-nAChR immunostaining, sections were microwaved in Tris buffer (pH 6) for 10 minutes. Following this step, sections were blocked in 5% horse serum (Chemicon, Temecula, CA) for 30 minutes and subsequently incubated with 1:400 diluted a9-nAChR antibody for 2 hours at room temperature. Following incubation with the primary antibodies, staining was developed according to the streptavidin-biotin-peroxidase method using a LSAB 2 kit purchased from DAKO (Carpinteria, CA). Briefly, sections were washed in phosphate-buffered saline and incubated with biotinylated anti-rabbit secondary antibody. They were then washed again in the same buffer and incubated in streptavidin-biotin-peroxidase complex. Staining was completed after incubation with substrate-chromogen solution. The length of incubation in solution with 3.3′-diaminobenzidine was determined by low-power microscopic inspection. Slides were then washed, dehydrated, and coverslipped using DPX (Sigma-Aldrich, St Louis, MO). Both adjacent sections and same slides were counterstained with hematoxylin for general histological orientation.
Statistical Methods
All data are expressed as means with 95% confidence intervals (CIs) of at least three determinations, unless stated otherwise. A paired t test was used to compare a9-nAChR mRNA expression in paired normal vs tumor tissues from breast cancer patients. A Mann-Whitney test was used to evaluate the effects of a9-nAChR mRNA expression on cell lines and on growth of tumor xenografts with increased (Tet-off) or diminished (siRNA) a9-nAChR expression in mice. The fold ratios of a9-nAChR mRNA expression detected in tumor vs normal samples (from surgical or laser capture microsdissected samples with different clinical staging criteria), were compared using the Scheffe test. Statistical differences in tumor cell proliferation, in vitro Tet-regulated a9-nAChR gene induction, [ 3 H]-nicotine receptor-binding activity, and soft agar assays were analyzed by the Kruskal-Wallis (nonparametric) test, and each pairwise comparison was made with the Mann-Whitney test. All statistical comparisons were performed using the SigmaPlot graphing software (San Jose, CA) and Statistical Package for the Social Sciences v.11.0.0 (SPSS, Chicago, IL). All statistical tests were two-sided. A P value of .05 or less was considered to indicate statistical significance.
Results
nAChR Expression in Human Breast Tumor Tissues and Breast Cell Lines
Previous studies have demonstrated that nicotine and its metabolites (eg, NNK) bind to nAChR subunits, which may mediate the carcinogenic effects of these tobacco components (16, 21) . Therefore, we characterized the expression of nAChR subunits in normal (nonmalignant) human breast cell lines (MCF-10A and HBL-100) and human breast cancer cell lines (MDA-MB-231, MDA-MB-453, AU-565, BT-483, and MCF-7). To evaluate the expression of nAChR subunits among Taiwanese breast cancer patients, human breast tumors (n = 50) and the surrounding normal tissues were dissected and subjected to RT-PCR separately. All breast cell lines were found to express similar (a5, a9, and a10) nAChR subunits (Figure 1, A) . The same three nAChR subunits (a5, a9, and a10) predominated in normal and malignant breast tissues (Figure 1, B) . We found increased a9-nAChR mRNA levels in nearly all tumor tissues compared with normal tissues (Supplementary Figure 1, A, available online). By contrast, mRNA levels for the a5-and a10-nAChR subunits were not substantially different between tumor and normal paired samples (data not shown).
Role of a9-nAChR in Growth of Human Breast Cancer Cells
To explore the possibility that the a9-nAChR subunit might play a role in smoking-induced human breast tissue tumorigenesis, we established a stable MDA-MB-231 cell line in which the expression of a9-nAChR was reduced by RNA interference. An MDA-MB-231 cell line with reduced expression of the a5-nAChR subunit was also generated as a control (Figure 1, C) . A cell line in which expression of both the a5-and a9-nAChR subunits were silenced could not be established because of the essential role of these subunits in cell survival. Rates of cell proliferation in parental MDA-MB-231 cells (231) and in such cells stably transfected with scrambled vector (Sc) or a5-nAChR (Si a5) siRNAs were statistically significantly increased after treatment with 1 µM NNK or 10 µM nicotine (for Sc cells on day 11, mean optical density [OD] 540 nm with dimethyl sulfoxide = 0.77, with nicotine = 1.35 and with NNK = 1.77; difference, nicotine vs control = 0.58, 95% CI = 0.48 to 0.68, P = .009; difference, NNK vs control = 1.00, 95% CI = 0.9 to 1.1, P = .009; for Si a5 cells on day 11, mean OD 540 nm with dimethyl sulfoxide = 0.77, with nicotine = 1.35, and with NNK = 1.78; difference, nicotine vs control = 0.58, 95% CI = 0.48 to 0.68, P = .009; difference, NNK vs control = 0.99, 95% CI = 0.89 to 1.09, P = .009) (Figure 1, D) . The rates of cell proliferation in Si a9 cells were statistically significant decreased after treatment with 10 µM nicotine, 1 µM NNK, and vehicle control when The membrane-associated a9-nAChR protein was detected in human MCF-7 breast cancer cells by immunofluorescence staining followed by confocal microscopy (Figure 1, E, arrowhead) . These results suggest that breast cancer cell proliferation induced by tobacco-specific carcinogenic components (such as NNK or nicotine) could be mediated through the endogenous a9-nAChR receptor. To test this hypothesis, MDA-MB-231 cells were treated with [ , and H157 (lung cancer) cells were also examined as described previously (16) . B) Relative mRNA expression of different nAChR subunits in normal and tumor human breast tissues isolated from 50 breast cancer patients. The cDNA was used for RT-PCR analysis, and the experiment was repeated twice. Percentage of occurrence is shown. C) Expression of the a5- and a9-nAChR subunits in stable MDA-MB-231 cell lines that express a9-nAChR (Si a9), a5-nAChR (Si a5), or scrambled (Sc) short interfering RNAs (siRNAs). Cell lines in which expression of the a5-or a9-nAChRs was specifically reduced were generated by transfection and G418 (4 mg/mL) selection. Levels of a5 and a9 mRNAs were determined by RT-PCR, and levels of the a5 and a9 proteins were determined by western blotting (WB). Expression of a9-nAChR mRNA in Human Breast Tumor Tissues As described above, the a9-nAChR subunit is important for nicotine-induced breast cancer cell proliferation. We next examined the mRNA levels of the a9-nAChR subunit in 276 tumor vs normal paired tissue samples by real-time PCR analysis (Figure 2, A  and B) . The PCR amplification curves were "left-shifted" in the tumor tissues (Figure 2 , A, red lines) relative to the profiles of normal tissues (green lines), indicating that the tumor samples overall contained greater quantities of a9-nAChR mRNA. The real-time PCR results were calculated, and the tumors were divided into two groups according to their a9-nAChR mRNA expression patterns. Here, 186 (67.3%) of the 276 normal vs tumor tissue pairs fell into the group in which expression of the a9-nAChR was higher in tumor than in normal tissue (T > N) and 90 paired samples had somewhat higher expression in normal than tumor tissue (N > T) (Figure 2, C) . In the group with higher tumor than normal expression (T > N) overall, the a9-nAChR expression Figure 2 , B, were subdivided into four groups depending on the extent of the difference in expression between tumor and normal tissue (less than twofold, two-to fivefold, five-to 10-fold, and >10-fold). The percentage of occurrences and the total number of tumor-normal pairs are presented for each category. D) Relative expression of a9-nAChR mRNA in tumor and normal tissue pairs grouped according to the clinical breast cancer stage. The tumor-normal tissue pairs for which relative levels of a9-nAChR mRNA were established in Figure 2 , B, were divided into five subgroups according to the clinical staging criteria as recommended by the American Journal of Critical Care. Data shown are the mean of the fold ratios of expression in paired tumor and normal tissues. Error bars indicate 95% confidence intervals. The numbers of paired samples at each stage are indicated above the bars. Data were analyzed with an overall nonparametric test (Kruskal-Wallis test), and multiple comparisons were assessed by the Mann-Whitney test. The comparison was carried out as follows: stage 0 vs stage 1, P = .66; stage 0 vs stage 2, P = .047; stage 0 vs stage 3, P < .001; stage 0 vs stage 4, P < .001. All P values are two-sided. E) Immunolocalization of the a9-nAChR protein in human invasive ductal and lobular carcinoma breast tumor tissues. The tumor tissues were cut into 8-µm serial sections and stained with antibodies specific to human a9-nAChR. N = normal; T = tumor; I.H.C. = immunohistochemistry stain; H.E. = hematoxylin and eosin stain. The normal breast cells are indicated by green arrows in a green frame, whereas the malignant breast cells are indicated by yellow arrows in a red frame. Scale bar = 200 µm.
in tumor cells was 7.84-fold greater than that of normal cells (copy number for normal cells = 73 638 vs tumor cells = 497 655, difference = 424 017, 95% CI = 285 647 to 709 664, P = .002). Also, more than fivefold increased a9-nAChR mRNA expression was detected in 57 (30.6%) of the 186 tumor tissues (Figure 2, C, bars 3 and 4) . However, in the group with higher normal than tumor expression (N > T), nearly all of the normal tissues had less than fivefold greater a9-nAChR expression than the paired tumor tissues (Figure 2 , C, bars 5 and 6).
Expression of a9-nAChR in Advanced-Stage Breast Tumor Tissues
We next categorized each tumor vs normal tissue pair according to the clinical stage of the tumor (Figure 2, D) . Advanced-stage tumors were associated with substantially higher levels of a9-nAChR mRNA expression. Data are presented as comparisons of the means of the fold ratios between paired tumor vs normal tissues and compared at each stage with the fold change of a9-nAChR mRNA expression levels in stage 0 (ductal carcinoma in situ) tumor vs normal paired tissues, as follows: stage 0 = 1.0-fold, stage 1 = 1.14-fold, stage 2 = 3.51-fold, stage 3 = 6.66-fold, stage 4 = 18.88-fold; difference, stage 0 vs 1 = 0.14-fold, 95% CI = 0.09-to 0.19-fold, P = .66; difference, stage 0 vs 2 = 2.51-fold, 95% CI = 1.39-to 3.63-fold, P = .047; difference, stage 0 vs 3 = 5.66-fold, 95% CI = 3.67-to 7.65-fold, P < .001; difference, stage 0 vs 4 = 17.88-fold, 95% CI = 9.22-to 26.54-fold, P < .001). To confirm these observations, laser capture-microdissected tumor and normal cells were harvested separately from 11 tumor samples. The a9-nAChR mRNA expression levels in the laser capture-microdissected cells were determined by real-time PCR analysis. The a9-nAChR mRNA expression level increased in a differentiation stage-dependent manner (stage 1 = 2.55-fold, stage 2 = 11.6-fold, stage 3 = 35.66-fold; difference, stage 1 vs 2 = 9.08-fold, 95% CI = 1.85-to 16.3-fold, P = .05; difference, stage 1 vs 3 = 33.1-fold, 95% CI = 8.24-to 57.97-fold, P = .05) (Figure 2 , D, and Supplementary  Figure 2 , C, available online). Next, a9-nAChR protein localization was determined by immunohistochemical staining of frozen tumor sections, which revealed an increase in a9-nAChR protein expression in advanced-stage tumor tissues diagnosed as invasive ductal and lobular carcinomas (Figure 2 , E, brown stain in red square frame indicated by the yellow arrows). By contrast, normal tissues did not express substantial levels of a9-nAChR (Figure 2 , E, green square frame indicated by the green arrows). In this study, no substantial changes in a9-nAChR mRNA and protein expression levels were detected in premalignant ductal carcinoma in situ lesions (diagnosed as stage 0) tumor vs normal paired samples (n = 10) (Figure 2 , D, bars 1 and 2, and Supplementary Figure 1 , B, available online).
Influence of a9-nAChR Expression on Growth of MDA-MB-231 Cells in Transformation Assays
In soft agar assays, the number of transformed colonies was statistically significantly reduced in MDA-MB-231 cells that carried a9-nAChR siRNA (Si a9) (Figure 3 , P = .009; tumor weight at 6 weeks, mice with Si a9 tumors vs mice with parental cell tumors, 1.23 vs 4.38 g, difference = 3.14 g, 95% CI = 2.31 to 3.97 g, P = .009) (Figure 3, C) . The tumor tissues were dissected from mice 6 weeks after tumor cell transplantation, and RT-PCR and western blot analysis revealed substantial inhibition of a9-nAChR mRNA and protein levels in tumors with a9-nAChR siRNA (Figure 3, E) . The mRNA expression level of a5-nAChR was unaltered in the same tumors (Figure 3, E) .
Effect of Overexpression of a9-nAChR on Transformation of Normal Human Breast Epithelial Cells and Tumor Growth in MCF-10A-Xenografted Mice
To investigate whether a9-nAChR is involved in smokinginduced transformation in normal human breast epithelial (MCF-10A) cells, we established MCF-10A (DOX) cells in which a9-nAChR gene expression was induced by removal of DOX. Real-time PCR analysis revealed that a9-nAChR mRNA expression in MCF-10A (DOX2) cells was maximally (>200-fold) induced 9-12 hours after removal of DOX (Supplementary Figure 3, A, upper right panel, and 3 , B, available online, P = .009). After 24 hours of removal of DOX, the levels of a9-nAChR protein were still substantially increased in MCF-10A (DOX2) cells compared with control MCF-10A (DOX+) cells (Supplementary Figure 3, C, available online, lanes 1-4) . The a9-nAChR-overexpressing MCF-10A (DOX2) cells exhibited increased cell proliferation compared with control MCF-10A (DOX+) cells (Figure 4 , A, empty vs solid triangle, day 7, mean OD 540 for DOX+ cells = 1.53, for DOX2 cells = 2.65, difference = 1.12, 95% CI = 1.01 to 1.23, P = .009). However, nicotine-or NNK treatment-induced cell proliferation was observed only in the MCF-10A (DOX+) cell line that expressed normal levels of the a9-nAChR.
Previous studies in an animal model revealed that normal human breast epithelial (MCF-10A) cells can also be transformed by NNK in vivo (9) . To mimic the long-term carcinogenic effects of nicotine to receptor binding on normal human breast epithelial cell transformation, MCF-10A (DOX+ or DOX2) cells were treated long term (60 days) with NNK (1 µM) or with nicotine (10 µM) according to the previously described methods (Supplementary  Figure 4 , A, available online) (9). The NNK-or nicotine-treated MCF-10A (DOX+ or DOX2) cells were then cultured in soft agar for an additional 21 days, and colony formation was evaluated microscopically (Figure 4, B) . More colonies were formed by NNK-treated MCF-10A (DOX2) cells compared with NNKtreated MCF-10A (DOX+) cells (Figure 4, B, bars 6 vs 3) . Interestingly, six colonies formed in the nicotine-treated MCF-10A (DOX2) cells (Figure 4 , B, bar 5), an observation that has never been reported previously (9) . Our results indicate that longterm exposure to lower concentrations of nicotine can induce transformation of normal breast epithelial cells and that a9-nAChR may play an important role in this process.
Two transformed cell lines were generated from soft agar colonies exposed to long-term treatment with nicotine or NNK: MCF-10A-Nic (DOX) and MCF-10A-NNK (DOX) (Figure 4 , B, bars 5 and 6; the cell morphologies are presented in Supplementary  Figure 4 , A, available online). We then sought to determine whether induction of a9-nAChR in the presence or absence of nicotine stimulation in vivo would effectively promote tumor growth (Supplementary Figure 5, available online) . BALB/c-nu/ nu mice (female, 4 weeks old) were injected subcutaneously with transformed MCF-10A-Nic (DOX) cells (5 × 10 6 ). After that, all mice bearing tumors (200 mm 3 ) were divided into either a9-nAChR mRNA expressing (DOX2) or nonexpressing (DOX+) groups in the presence or absence of nicotine (10 mg/mL) in their ) were injected subcutaneously into the back of each NOD. CB17-PRKDC(SCID)/J (NOD-SCID) mouse (n = 5). After tumor transplantation, nicotine (10 mg/mL) was administered via the drinking water for 6 weeks until the mice were killed (21) . The gross appearance of the tumors was observed 6 weeks after drug treatment. C and D) Tumor volumes and weights in mice from (B). Tumor samples from each group were analyzed as described in "Materials and Methods" (21) . Data represent the mean tumor volume (C) and tumor weight (D) for 10 mice per group. Error bars indicate the 95% confidence intervals. In (C), tumors from MDA-MB-231 cells with a9-nAChR siRNA (Si a9) were statistically significantly smaller than those from parental (231) or control (Sc) cells with or without nicotine treatment (P = .009). In (D) tumors in nicotine-treated mice that were injected with MDA-MB-231 (231) cells (P = .027) or scrambled vector control (Sc) cells (P = .009) were heavier if the mice were fed nicotine. In comparison, tumors in mice that had been injected with MDA-MB-231 cells containing a9-nAChR siRNA (Si a9) were statistically significantly smaller than both of the other groups in the presence or absence of nicotine treatment (P = .009). Data were analyzed by nonparametric tests (Kruskal-Wallis and Mann-Whitney test); all P values are two-sided. E) Expression of nAChR subunits in tumors with silencing RNAs. Tumors were dissected from mice at the end of the experiment. Total RNA and protein lysates were isolated from the tumor tissues, and a9- and a5-nAChR mRNA and protein expression were detected by reverse transcription-polymerase chain reaction (RT-PCR) and by western blotting (WB), respectively. b-glucuronidase (GUS) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression served as controls. The Si a9 group was statistically significantly different from both the Sc and 231 groups (P = .009). A previous article indicated that the tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation, which causes hypermethylation of the promoters of tumor suppressor genes in Taiwanese lung cancer patients (35) . However, it is difficult to provide the direct evidence of smoking-related a9-nAChR-mediated Comparisons were performed for DOX+ Nic2 vs DOX+ Nic+ (P = .009) and DOX+ Nic+ vs DOX2 Nic+ (P = .016). Data were analyzed by a nonparametric test (Kruskal-Wallis and Mann-Whitney test); all P values are two-sided. D) Expression of a9-nAChR subunits in MCF-10A (DOX+ or 2) tumors. At the end of the experiment in (C), the mice were killed and the tumors dissected to determine the levels of a9-nAChR mRNA and protein by using reverse transcription-polymerase chain reaction (RT-PCR) or western blotting (WB), respectively. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression served as a control. E) Immunolocalization of a9-nAChR protein in MCF-10A-Nic (DOX)-xenografted breast tumor tissues. Strong immunoreactivity for a9-nAChR was detected in the DOX2 but not the DOX+ mouse tumor tissues (arrowhead). Scale bar = 100 µm. C, vehicle control; Tet-off, removal of tetracycline (DOX).
carcinogenic effects in human breast cancer. We performed an epidemiological cohort study to assess the clinical significance of a9-nAChR expression in different stages of breast tumors and to correlate it to smoking history among Taiwanese women. In this study, 174 breast tumor patients were recruited for evaluation of tobacco smoking history, clinical staging criteria, and a9-nAChR mRNA expression analysis of tumor vs normal paired samples (Supplementary Table 3 , available online). The results indicate that seven (38%) of the 18 breast tumor tissues were diagnosed as later stages (3) (4) in the smoker group. By contrast, a similar occurrence ratio was detected but shifted to early-stage (0-1) tumors in the passive (19 of 52, 36.5%) and nonsmoker groups (40 of 104, 38%). Furthermore, we found increased expression of a9-nAChR mRNA in tumor tissues from current smokers compared with those from nonsmokers (6.62-vs 1.51-fold, difference = 5.11-fold, 95% CI = 2.67-to 7.55-fold, P = .003). By contrast, a lower fold ratio of a9-nAChR mRNA expression was detected in tumor tissues from passive smokers compared with nonsmokers (2.81-vs 1.51-fold, difference = 1.3-fold, 95% CI = 0.79-to 1.81-fold, P = .256). In this study, direct evidence for the nicotinic binding activity of a9-nAChR in human breast cancer was also provided by a [ 3 H]-nicotine-binding assay (Figure 1, F) . These observations have led to the conclusion that nicotine binding to nAChR may play a direct role in the promotion and progression of human breast cancers.
Discussion
In this study, our results demonstrate that reduction of a9-nAChR subunit expression by RNA interference in human breast cancer cells substantially inhibits tumor growth in vitro and in vivo. By contrast, we conclude that the a9-nAChR subunit is potentially carcinogenic in normal human breast epithelial cells in vitro and in vivo as shown by the properties of a9-nAChR-overexpressing MCF-10A cells. Observation of clinical specimens has indicated that a9-nAChR expression is generally higher in tumor cells relative to normal cells. Levels of a9-nAChR expression in human breast tumor cells are generally increased in more advanced-stage breast cancers.
A recent study demonstrated that binding of exogenous nicotine and acetylcholine to nAChRs and mAChRs, respectively, stimulates the growth of both small cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs) (36) . A similar study also showed that the autocrine interaction of acetylcholine with the nAChR stimulates SCLC cell proliferation (37) . To identify genetic factors involved in smoking-mediated cancer risk, a genome-wide association study of 317 139 single-nucleotide polymorphisms was recently performed using DNA from 1989 lung cancer patients and 2625 control subjects from six central European countries (38) . A locus in the 15q25 chromosome region was strongly associated with lung cancer (P = 9 × 10 210 ) (39). Interestingly, this region contains several genes, including three nAChR subunits (CHRNA5, CHRNA3, and CHRNB4, encoding the a5, a3, and b4 subunits, respectively) that are expressed in neurons and other tissues (particularly alveolar epithelial cells, pulmonary neuroendocrine cells, and lung cancer cell lines) (38, 40, 41) . These nAChR subunits also bind to N-nitrosonornicotine as well as potential lung carcinogens (18, 42) .
We present substantial evidence of the expression of the three major nAChR subunits (a5, a9, and a10) in human breast cancer tissues. However, we found that the mRNA expression levels of a10-nAChR were not substantially different between tumor and normal tissues. This could be explained by the fact that a10-nAChR is structurally similar to a9-nAChR, with 58% amino acid sequence identity. Based on the sequence similarity, the a9 subunit belongs to a family of ligand-gated channels that includes subunits for the receptors of the neurotransmitters acetylcholine, gamma-aminobutyric acid, glycine, and serotonin (43) . Most of the neuronal-nAChR subunits (a1-a10 and b2-b4 nAChRs) and the muscle subunit (M1-M4 nAChRs) share between 48% and 70% sequence identity. However, the sequence identity between a9 and all other known nAChR subunits is less than 39% (43). As described above, a9-nAChR subunits can assemble into a homopentameric receptor-channel complex (14, 15) or form a heteropentameric receptor with the a5-nAChR subunits (40) , similar to the behavior of a7 and a8 neuronal-nAChR subunits. This observation implies that the structure of the a9-nAChR gene differs from those of known nAChR subunit genes (44) (45) (46) , suggesting that a9-nAChR represents a divergent branch within the nAChR gene family.
The a9-and a10-nAChR subunits are expressed primarily within the cochlear and vestibular hair cells of the inner ear and have been implicated in auditory processing (43, 47) . Previous studies have demonstrated that the a10-nAChR subunit fails to produce functional receptors on its own (48, 49) . However, coinjection of a9-and a10-nAChR into Xenopus laevis oocytes results in the appearance of an unusual nAChR subtype that displays unusually fast and extensive agonist-mediated desensitization, a distinct current-voltage relationship, and a biphasic response to changes in extracellular Ca 2+ ions (50) . The observed effects could be because of the activation of the a9-and a10-nAChR subunits because they are most likely to be found in the functional receptor in vivo (47, 48) . Coexpression of the a9-and a10-nAChR subunits in normal cells has been described in very restricted cell types, such as bronchial epithelia (16) , pituitary pars tuberalis (48) , olfactory epithelia (48), cochlea (47, 48) , keratinocytes (51, 52) , and, in this study, breast tissue. A previous study indicated that the a9-and a10-nAChRs are expressed by the lung parenchyma and alveolar macrophages of isogenic lung transplants. Their expression increases during rejection in pulmonary allografts (53) . Furthermore, a9-nAChR is one of a number of self-antigens targeted by autoantibodies produced in patients with pemphigus (54) . These studies suggest that the a9-and a10-nAChR may represent a potential therapeutic target for ear disorders (49) , pemphigus (54) , and neuropathic pain (55) ; it may also inhibit the proinflammatory functions of alveolar macrophages and afford protection to pulmonary transplants (53) . Our results, as well as results from other groups, suggest that the a10-nAChR subunit probably associates with the a9-nAChR subunit in vivo to form a novel subtype of nicotinic receptor involved in different physiological systems, further illustrating the potential involvement of these receptors in tumor carcinogenesis (48) .
Previous studies have demonstrated that the a9-and a10-nAChRs are present in human lung airway epithelia (SAEC, NHBE) (16) and lung carcinoma cells (H157, SCLC, and NSCLC) (16) , which play a part in the autocrine-proliferative network that facilitates the growth of neoplastic cells (37) . Another study demonstrated that activation of a9-nAChR signaling elevated the phosphorylation status of adhesion molecules, which directly regulate cell-matrix and cell-cell adhesion in normal human keratinocytes (51) . These results suggest the existence of a novel biological mechanism of a9-nAChR signaling in normal epithelial cell motility that has clinical implications for cancer metastasis. Our data also demonstrate that overexpression of the a9-nAChR subunit in transformed normal human breast epithelial MCF-10A-Nic (DOX2) cells increased anchorage-independent colony formation in soft agar assays in response to nicotine treatment. These results are consistent with those described above (36, 37) , implying that overexpression of a9-nAChR signaling triggers an autocrine loop in which nicotine more readily interacts with and activates the a9-nAChR. This loop stimulates premalignant transformation in normal human breast epithelial cells and increases tumor growth in MCF-10A-xenografted mice.
There are some limitations to our study. First, the breast tumor tissues in this study were limited in number and presumably all from Asian patients. Our data highlight the urgent need for demographic studies of a9-nAChR expression in breast tumor patients from diverse genetic backgrounds. Breast cancer in Taiwan is particularly characterized by its low incidence rate and its early age of tumor onset (56) . Additional multiracial cohort studies should be performed to investigate whether this disparity in breast cancer occurrence is because of differential racial risks related to a9-nAChR expression and/or differences in socioeconomic status (education, occupation, or cigarette smoking). Also, to examine the prognostic value of a9-nAChR mRNA expression in breast cancer patients with different stages, we measured a9-nAChR mRNA by real-time PCR either in surgical and laser capture-microdissected tumor samples. Our results suggest that higher a9-nAChR mRNA expression is associated with laterstage disease among breast cancer patients. However, our study included only a small number of stage 4 samples (n = 4) and should therefore be considered as exploratory. Further investigations that include more late-stage (stage 4) patient tumors are urgently needed.
Nicotine, from smoking, and its metabolite NNK are considered to be a carcinogens that react with DNA, and most reports have suggested the chemical properties of the resulting DNA adducts to cause the many genetic changes known to exist in human cancers (35, 57, 58) . In this study, to explore whether the nicotinic receptor-mediated biological mechanisms may play a decisive role in tumor formation, the a9-nAChR expression in human breast cancer (MDA-MB-231) and normal (MCF-10A) cells were forcibly changed by RNA interference and adenovirus (Tet-Off) experiments, respectively. Our data demonstrate that the nicotine-and NNK-induced cancer cell proliferation effects were inhibited in the a9-nAChR cells that expressed siRNA to the a9-nAChR. By contrast, substantially increased tumor growth was seen in the MCF-10A-Nic (DOX2) tumors that expressed higher levels of a9-nAChR compared with MCF-10A-Nic (DOX+) tumors that expressed normal levels of a9-nAChR. These results imply that receptor-mediated carcinogenic signals play a decisive role in biological functions related to human breast cancer development. In the future, the molecular mechanisms whereby the a9-nAChR is involved in smoking-induced disease should be further investigated.
